STML News and Press, Stemline Therapeutics Inc. From 12/06/19

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced the appointment of Robert M. Francomano as Chief Commercial O...

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted three upcoming ELZONRIS (tagraxofusp), presentations, including a...

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Stemline management will present at Piper Jaffray’...

Image source: The Motley Fool. Stemline Therapeutics Inc   (NASDAQ: STML) Q3 2019 Earnings Call Nov 8, 2019 , 8:00 a.m. ET Operator Continue reading

Stemline Therapeutics, Inc. (STML) Q3 2019 Earnings Conference Call November 8, 2019, 08:00 AM ET Company Participants Kenneth Hoberman - COO Ivan Bergstein - CEO Robert Francomano - SVP, Global Head, Commercial David Gionco - CAO Conference Call Participants Jessica Fye ...

Stemline Therapeutics (NASDAQ: STML ): Q3 GAAP EPS of -$0.34 beats by $0.12 . More news on: Stemline Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Net revenue for ELZONRIS ® was $13.3 million for the third quarter New patient starts estimated to have increased greater than 20% from last quarter Conference call and live webcast scheduled for tomorrow, Friday November 8 th , at 8:00 AM ET NEW YORK, Nov. 07, 2019 (GLOBE...

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp; SL-401), a novel targeted therape...

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will host a conference call and webcast on F...

NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS ® (tagraxofusp) clinical data from the pi...